CLL: Stages, Treatments & Side Effects
- Treatment for chronic lymphocytic leukemia (CLL), a type of blood cancer, is highly individualized. Many patients begin with a watch‑and‑wait approach and do not being treatment until symptoms or tests reveal the cancer is progressing.
- “When we get to the point where we have issues and symptoms from the disease,” that’s when treatment becomes necessary, Dr. George Yaghmour, a hematologist at USC Norris Cancer Center, tells SurvivorNet.
- Modern CLL care relies on targeted therapies such as BTK inhibitors, BCL‑2 inhibitors, and monoclonal antibodies, which have largely replaced chemotherapy due to their effectiveness and more manageable side‑effect profiles.
- Side effects vary by treatment type — from blood count changes and gastrointestinal symptoms to infusion reactions — but newer targeted options have significantly improved long‑term disease control, remission rates, and overall quality of life for many patients.
“CLL is a disease we easily just don’t have to do anything and patient has to be just monitored and that’s the watch and wait period,” Dr. George Yaghmour, a hematologist faculty member at USC Norris Cancer Center in Los Angeles, tells SurvivorNet. “But when we get to the point where we have issues and symptoms from the disease, that’s the point where quality of life comes into play to get those symptoms controlled.”
Read MoreHow is CLL Staged?
Based on results from the Rai system, physical exams, and blood tests, CLL is divided into 5 stages:- Stage 0: No enlargement of the lymph nodes, spleen, or liver, with red blood cell and platelet counts near normal
- Stage I: Lymphocytosis (high lymphocyte count) with enlarged lymph nodes, though the liver and spleen are not enlarged, with red blood cell and platelet counts near normal
- Stage II: Lymphocytosis with liver and/or spleen enlarged; lymph nodes may or may not be enlarged, and red blood cell and platelet counts are still near normal
- Stage III: Lymph nodes, liver, or spleen may or may not be enlarged; red blood cell counts are low, which is considered anemia, yet platelet counts are still near normal
- Stage IV: Lymphocytosis with enlarged lymph nodes, spleen, or liver; red blood cell counts are low, and platelet counts are low, which is known as thrombocytopenia
Treatment Options for CLL
In the early stages, doctors typically use a “watch and wait” approach, monitoring the patient’s condition with regular checkups and blood tests, since CLL grows so slowly that treatment is not needed right away, especially if the person is not showing symptoms.Studies have shown that starting treatment before symptoms develop does not improve survival for most people with early-stage CLL, so watch and wait helps patients avoid unnecessary side effects until treatment is truly needed.
For stage III and IV, patients need active therapy. This might include:
- BTK Inhibitors: A targeted therapy that aims at cancer specifically rather than attacking the rest of the body and hoping to kill the cancer in the process
- BCL-2 Inhibitors: Targeted drugs that block the BCL-2 protein, which helps cancer cells survive
- Monoclonal antibodies: Targeted therapies that bind to specific markers on cancer cells, helping the body’s immune system attack them
- Chemoimmunotherapy: Pairs chemotherapy with targeted antibody drugs that attack CLL cells
BTK inhibitors and BCL-2 inhibitors have become the preferred first-line treatments for many patients with CLL due to their effectiveness and generally more favorable side-effect profiles, and chemoimmunotherapy is now less commonly used.
RELATED: The New Approach to CLL Treatment
The introduction of BTK inhibitors and other targeted drugs has changed the treatment of CLL and improved the outlook for people with this cancer.
“In terms of BTK inhibitors, there are different generations and different profiles,” Dr. Yaghmour explains to SurvivorNet.
Side Effects From BTK Inhibitors
Dr. Yaghmour explains that toxicity profiles vary between different generations of BTK inhibitors, but “the toxicity profile will generally include nausea, vomiting, headaches,” he says.
“We monitor for blood clots or thrombosis risk and arrhythmia and blood pressure, and generally those are the common side effects, and we monitor for risk of infection symptoms as well,” Dr. Yaghmour adds.
Expert Resources for CLL Patients
The most common side effects with BTK inhibitors include:
- Lower than normal levels of white and red blood cells
- Diarrhea
- Nausea
- Fatigue
- Muscle and joint aches
- Headache
- Easy bruising
Additional side effects, such as irregular heart rhythm and infections, are possible as well, and patients should keep their doctors informed if anything feels off.
Side Effects from BCL-2 Inhibitors
BCL-2 inhibitors, such as venetoclax, can cause some similar side effects to BTK inhibitors, though these targeted treatments are still generally better tolerated than chemotherapy.
Potential side effects include:
- Low white blood cell counts (neutropenia), which can increase the risk of infection
- Fatigue
- Nausea
- Diarrhea
- Constipation
- Upper respiratory tract infections
- Joint or muscle pain
- Headache
Monoclonal Antibodies & Chemoimmunotherapy
Monoclonal antibodies used to treat CLL — such as rituximab, obinutuzumab, and ofatumumab — can cause side effects, particularly during or shortly after the infusion.
The most common side effects are infusion-related reactions, such as:
- Fever
- Chills
- Rash
- Difficulty breathing
Patients may also experience fatigue, nausea, low white blood cell counts, and an increased risk of infections. Healthcare teams monitor patients closely during treatment and can often manage infusion reactions with medications and by slowing the infusion rate.
Common side effects of chemoimmunotherapy — which is, again, used less often in recent years for CLL — include fatigue, nausea, infusion reactions, low blood cell counts, and an increased risk of infections.
While advanced CLL can cause significant symptoms, treatment options have improved dramatically in recent years. Targeted therapies, monoclonal antibodies, and other newer treatments can often control the disease for years, relieve symptoms, reduce complications, and improve quality of life.
Many patients with advanced CLL are able to achieve long periods of remission with modern therapies.
Questions To Ask Your Doctor
- What side effects should I monitor for while taking a BTK inhibitor?
- Is there anything I can do to reduce side effects?
- What should I do if I experience an unexpected side effect?
- What are my options if side effects become too difficult?
Learn more about SurvivorNet's rigorous medical review process.
